[go: up one dir, main page]

MA56748B1 - Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées - Google Patents

Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées

Info

Publication number
MA56748B1
MA56748B1 MA56748A MA56748A MA56748B1 MA 56748 B1 MA56748 B1 MA 56748B1 MA 56748 A MA56748 A MA 56748A MA 56748 A MA56748 A MA 56748A MA 56748 B1 MA56748 B1 MA 56748B1
Authority
MA
Morocco
Prior art keywords
solid forms
diflooro
neopentylamino
pentanamide
tetrahydronaphthalen
Prior art date
Application number
MA56748A
Other languages
English (en)
Inventor
Elaine Greer
Stephen Anderson
Mark MALONEY
Shu Yu
Ekaterina Albert
Emily Rigsbee
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority claimed from EP19758589.6A external-priority patent/EP4010322B1/fr
Publication of MA56748B1 publication Critical patent/MA56748B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne : a) des formes à l'état solide de sels de bromhydrate du composé 1; b) des compositions pharmaceutiques comprenant une ou plusieurs formes à l'état solide de sels de bromhydrate du composé 1, et, éventuellement, un excipient pharmaceutiquement acceptable; c) des méthodes de traitement de tumeurs ou de cancers par administration d'une ou de plusieurs formes à l'état solide de sels de bromhydrate du composé 1 à un sujet en ayant besoin; et d) des procédés de préparation des formes à l'état solide du composé 1.
MA56748A 2019-08-09 2019-08-09 Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées MA56748B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/537,394 US10590087B1 (en) 2019-08-09 2019-08-09 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
EP19758589.6A EP4010322B1 (fr) 2019-08-09 2019-08-09 Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
PCT/US2019/045948 WO2021029854A1 (fr) 2019-08-09 2019-08-09 Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées

Publications (1)

Publication Number Publication Date
MA56748B1 true MA56748B1 (fr) 2025-12-31

Family

ID=69778968

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56748A MA56748B1 (fr) 2019-08-09 2019-08-09 Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées

Country Status (8)

Country Link
US (10) US10590087B1 (fr)
JP (1) JP2024149803A (fr)
KR (1) KR20250030524A (fr)
FI (1) FI4010322T3 (fr)
MA (1) MA56748B1 (fr)
MX (1) MX2025004371A (fr)
TW (2) TWI867022B (fr)
ZA (1) ZA202202325B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884634B2 (en) * 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
US20230049311A1 (en) * 2019-08-09 2023-02-16 Springworks Therapeutics, Inc. Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
FI4010322T3 (fi) * 2019-08-09 2025-12-16 Pfizer (s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttö
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma
CN116033895A (zh) 2020-08-20 2023-04-28 小利兰·斯坦福大学托管委员会 用于治疗以黏液分泌过多为特征的呼吸系统疾病的方法
IL311128A (en) 2021-09-01 2024-04-01 Springworks Therapeutics Inc Synthesis of neurogestate
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
CA3237521A1 (fr) * 2021-11-05 2023-05-11 Springworks Therapeutics, Inc. Compositions et traitements a base de nirogacestat
JP2025503231A (ja) * 2022-02-01 2025-01-30 スプリングワークス、セラピューティクス、インコーポレイテッド ニロガセスタットによる卵巣癌の治療
WO2023174390A1 (fr) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 Forme cristalline de dihydrobromure de nirogacestat, son procédé de préparation et son utilisation
WO2023225283A1 (fr) 2022-05-20 2023-11-23 Springworks Therapeutics, Inc. Traitements avec du nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
KR20250155587A (ko) * 2023-03-09 2025-10-30 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 니로가세스타트 디히드로브로마이드의 결정형, 및 이의 제조 방법 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5160260A1 (es) 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
US10211310B2 (en) 2012-06-12 2019-02-19 Novellus Systems, Inc. Remote plasma based deposition of SiOC class of films
WO2015092614A1 (fr) 2013-12-20 2015-06-25 Pfizer Inc. Altérations d'activation de notch dans le cancer du sein
CA2990564A1 (fr) * 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Derive d'amide heterocyclique bicyclique
WO2018045273A2 (fr) 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions et méthodes pour le traitement de néoplasies
WO2019053727A1 (fr) 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. Redifférenciation de cellules développées in vitro à partir de cellules bêta d'îlots pancréatiques humains adultes par des inhibiteurs à petites molécules de la voie de signalisation
US20220133672A1 (en) * 2018-12-18 2022-05-05 The University Of North Carolina At Chapel Hill Notch inhibitors for the treatment of vascular malformations
FI4010322T3 (fi) 2019-08-09 2025-12-16 Pfizer (s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttö
US20230049311A1 (en) 2019-08-09 2023-02-16 Springworks Therapeutics, Inc. Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

Also Published As

Publication number Publication date
MX2025004371A (es) 2025-05-02
US11566006B2 (en) 2023-01-31
US20210040045A1 (en) 2021-02-11
KR20250030524A (ko) 2025-03-05
US10941118B2 (en) 2021-03-09
TW202525782A (zh) 2025-07-01
US11884635B2 (en) 2024-01-30
US12297177B2 (en) 2025-05-13
US20240051924A1 (en) 2024-02-15
US20210269407A1 (en) 2021-09-02
TWI867022B (zh) 2024-12-21
US20230202987A1 (en) 2023-06-29
US10590087B1 (en) 2020-03-17
US20240150299A1 (en) 2024-05-09
FI4010322T3 (fi) 2025-12-16
US12116347B2 (en) 2024-10-15
US10710966B1 (en) 2020-07-14
US20230406827A1 (en) 2023-12-21
TW202120482A (zh) 2021-06-01
US11905255B1 (en) 2024-02-20
US11820748B2 (en) 2023-11-21
US20230167069A1 (en) 2023-06-01
ZA202202325B (en) 2024-06-26
JP2024149803A (ja) 2024-10-18
US20230382872A1 (en) 2023-11-30
US11845732B2 (en) 2023-12-19

Similar Documents

Publication Publication Date Title
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
MX2023007192A (es) Inhibidores de prmt5.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
MX2024011056A (es) Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d.
MX2025000772A (es) Compuesto heterociclico que actua sobre la proteina kras mutante g12d
EP4643882A3 (fr) Inhibiteurs de capsides pour la prévention du vih
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
JP2021038257A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
WO2021168483A3 (fr) Traitement d'infections à coronavirus humain à l'aide d'inhibiteurs de traitement de glycoprotéine alpha-glucosidase
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
TN2022000092A1 (en) Oral complement factor d inhibitors
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
JOP20220076A1 (ar) مثبطات عامل d المكمل عن طريق الفم
MA33109B1 (fr) Traitement d'un cancer du pancreas